Mingyaotang Pharmaceutical Technology Development Overview

  • Founded
  • 1992
Founded
  • Status
  • Private
  • Latest Deal Type
  • Later Stage VC
  • Investors
  • 1

Mingyaotang Pharmaceutical Technology Development General Information

Description

Developer and provider of household medical products integrating biofiber and other modern technologies with basic health products. The company's products include nasal paste products, sterilized band-aids and cotton balls.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Medical Supplies
Other Industries
Pharmaceuticals
Primary Office
  • Ji County
  • Cangzhou, Hebei 061000
  • China
+86 0317 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Mingyaotang Pharmaceutical Technology Development Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Later Stage VC Completed Generating Revenue
To view Mingyaotang Pharmaceutical Technology Development’s complete valuation and funding history, request access »

Mingyaotang Pharmaceutical Technology Development Executive Team (1)

Name Title Board Seat Contact Info
Yuqiang Li Ph.D Chairman & General Manager
To view Mingyaotang Pharmaceutical Technology Development’s complete executive team members history, request access »

Mingyaotang Pharmaceutical Technology Development Board Members (1)

Name Representing Role Since
Yuqiang Li Ph.D Mingyaotang Pharmaceutical Technology Development Chairman & General Manager 000 0000
To view Mingyaotang Pharmaceutical Technology Development’s complete board members history, request access »

Mingyaotang Pharmaceutical Technology Development Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Tianxing Capital Venture Capital Minority 000 0000 000000 0
To view Mingyaotang Pharmaceutical Technology Development’s complete investors history, request access »